Referência de medicamentos
Tisotumab vedotin
Tisotumab vedotin is a medicine in the class oncology. It is used for cervical cancer.
- Classe do medicamento: Oncology
- Indicado para: cervical cancer
Última atualização Fontes: US FDA label
Para profissionais de saúde — apenas referência. Esta página é um resumo breve, não é aconselhamento médico nem substitui a bula oficial ou o julgamento clínico. Verifique sempre antes de prescrever ou dispensar.
O conteúdo clínico desta página está disponível apenas em inglês.
Pontos-chave
- Classe do medicamento
- Oncology
- Código ATC
- L01FX23
- Formas farmacêuticas comuns
- injeção
- Concentrações comuns
- 40 mg/4 ml
- Interações conhecidas
- 7 (Moderada: 7)
- Nomes comerciais
- 2
- Países e mercados
- 2
Para que é usado
Como funciona
Tissue factor-directed antibody drug conjugate. The ADC binds TF-expressing cancer cells and is internalized. MMAE is then released by proteolytic cleavage, disrupting the microtubule network and causing cell cycle arrest and apoptotic cell death.
Dose habitual em adultos (resumo da bula)
Recurrent or metastatic cervical cancer with disease progression on or after chemotherapy: 2 mg/kg (maximum 200 mg for patients ≥100 kg) IV infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity
Gravidez e amamentação
- Gravidez
- Unsafe Can cause fetal harm: no human data; its MMAE payload caused fetal deaths and malformations in rats below human exposure. Check pregnancy status before starting; contraception during and for 2 months after the last dose (men with female partners: 4 months).
- Amamentação
- Unsafe No human milk data. The antibody is large and poorly absorbed, but the small MMAE payload might reach the infant. Do not breastfeed during treatment and for 3 weeks after the last dose.
Efeitos adversos relatados
- Hemoglobin decreased
- Peripheral neuropathy
- Conjunctival adverse reactions
- Nausea
- Fatigue
- Aspartate aminotransferase increased
Advertências de caixa preta
- Ocular toxicity: can cause severe ocular toxicities, including changes in vision, severe vision loss and corneal ulceration. Conduct an ophthalmic exam (symptoms, visual acuity, slit lamp exam) before starting, before every cycle for the first nine cycles, and as clinically indicated. Adhere to required premedication and eye care. Withhold until improvement, then resume, reduce the dose, or permanently discontinue based on severity.
Quem deve ter cuidado
- Severe ocular adverse reactions (conjunctivitis, keratopathy, dry eye) occurred in 55% of patients; eye exams and eye care are required.
- Peripheral neuropathy occurred in 39% of patients; monitor and withhold, reduce or discontinue based on severity.
- Hemorrhage occurred in 51% of patients; permanently discontinue for pulmonary or CNS hemorrhage.
Informe ao farmacêutico ou ao médico sobre gravidez ou amamentação, doença renal ou hepática, alergias e todos os outros medicamentos ou suplementos que você usa.
Principais interações (7)
- Chloramphenicol + Tisotumab vedotin Moderate
- Clarithromycin + Tisotumab vedotin Moderate
- Itraconazole + Tisotumab vedotin Moderate
- Ketoconazole + Tisotumab vedotin Moderate
- Mifepristone + Tisotumab vedotin Moderate
- Posaconazole + Tisotumab vedotin Moderate
- Tisotumab vedotin + Voriconazole Moderate
Para assinantes do Pro+
Desbloqueie a página completa
Crie uma conta e comece um teste do Pro+ para abrir a monografia completa de Tisotumab vedotin: doses, gravidez e amamentação, efeitos adversos, advertências e todas as interações.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Dosing in older adults
- How to give it
- Pharmacokinetics
- Patient counselling points
- IV preparation and dilution
Experimente o Pro+ grátis por 7 dias na web. Sem cartão.
Outros medicamentos desta classe
Perguntas frequentes
What is Tisotumab vedotin used for?
Tisotumab vedotin is a medicine in the class oncology. It is used for Cervical cancer.
What side effects have been reported with Tisotumab vedotin?
Hemoglobin decreased, Peripheral neuropathy, Conjunctival adverse reactions, Nausea, Fatigue, Aspartate aminotransferase increased. Serious warning: Ocular toxicity: can cause severe ocular toxicities, including changes in vision, severe vision loss and corneal ulceration.
Can Tisotumab vedotin be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm: no human data; its MMAE payload caused fetal deaths and malformations in rats below human exposure. Check pregnancy status before starting; contraception during and for 2 months after the last dose (men with female partners: 4 months). Breastfeeding: Unsafe. No human milk data. The antibody is large and poorly absorbed, but the small MMAE payload might reach the infant. Do not breastfeed during treatment and for 3 weeks after the last dose.
What does Tisotumab vedotin interact with?
MediHelp lists 7 known interactions for Tisotumab vedotin. Moderate: 7. The most serious include Chloramphenicol, Clarithromycin, Itraconazole.
Monografias completas, posologia e verificador de interações no app MediHelp
Abra a referência completa, verifique interações entre vários medicamentos e use as ferramentas de posologia no app MediHelp.
